Pharma-Bio Serv, Inc.

What they do

Pharma-Bio Serv provides compliance, project management, and technology transfer support consulting to pharmaceutical, biotechnology, chemical, medical device, cosmetic, food, and allied products industries. Its core business is FDA and international agency regulatory compliance consulting. The company serves clients in Puerto Rico, the United States, Europe, and Brazil.

Revenue drivers

• Regulatory compliance consulting — Core business; revenues in the six months ended April 30, 2026 were $5.0M, up from $4.9M in the prior-year period.
• Project management and technology transfer support — Part of the service offering; no separate segment disclosure provided.
• Geographic markets — Services to clients in Puerto Rico, US, Europe, and Brazil; no revenue split by geography disclosed.

Recent performance

For the quarter ended April 30, 2026, revenues were $2.7M, up from $2.4M in the same quarter last year; net income was $0.23M versus $0.10M. For the six months, revenues were $5.0M versus $4.9M, and net income was $0.27M versus $0.10M. Cash and equivalents were $1.8M at April 30, 2026, down from $3.4M at October 31, 2025. The company had total assets of $11.5M and no long-term debt, with total liabilities of $1.0M.

Strategy

Management stated a 'continued strategic focus on markets that offer the greatest opportunities for return, combined with disciplined cost management and operational efficiency' to improve profitability. The company has maintained a lean cost structure, with selling, general and administrative expenses declining from $1.78M to $1.57M in the first half of fiscal 2026. It holds a portfolio of marketable securities ($6.7M) and has a buyback program (treasury stock increased slightly).

Risks

• Revenue concentration in regulatory consulting — Core business depends on FDA and international agency compliance work; any decline in regulatory demand could materially affect results.
• Geographic concentration in Puerto Rico — A significant portion of clients are in Puerto Rico; local economic or pharmaceutical industry downturns could reduce demand.
• Recent revenue decline — Annual revenue fell from $20.1M in 2021 to $9.0M in 2025, indicating a sustained contraction in business.
• Cash burn — Operating cash flow was negative in 2024 and 2025, and cash declined by $1.6M from October 31, 2025 to April 30, 2026.

Outlook

Management expressed encouragement about the latest quarter's profitability improvement but offered no explicit revenue or earnings guidance. The forward-looking statements caution that actual results may differ materially from expectations due to risk factors in the Form 10-K. The company continues to focus on higher-return markets and cost discipline.